April 9, 2020 10:13 AM EDT

Pfizer nabs colorectal cancer OK for Braftovi; Bristol Myers, Pfizer pull out of regional deal with Portola

ENDPOINTS

→ Ten months after Array showed off the positive BEACON-CRC data that enticed Pfizer to write a $11.4 billion buyout check, the pharma giant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer nabs colorectal cancer OK for Braftovi; Bristol Myers, Pfizer pull out of regional deal with Portola

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pfiz­er nabs col­orec­tal can­cer OK for Braftovi; Bris­tol My­ers, Pfiz­er pull out of re­gion­al deal with Por­to­la

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pfizer nabs colorectal cancer OK for Braftovi; Bristol Myers, Pfizer pull out of regional deal with Portola